FDA Nixes Innovator Industry-Backed Changes To Citizen Petition Rule
Executive Summary
Agency rejects PhRMA requests to ease certification process and limit rule's application; separately, law firm Hyman, Phelps & McNamara objects to FDA practice of delaying ANDA approval announcements until it issues a petition decision.